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Abstract
Background: Chemo-resistance is still a major obstacle in efforts to overcome acute myeloid leukemia (AML). An
emerging concept has proposed that interactions between the bone marrow (BM) microenvironment and leukemia
cells reduce the sensitivity of the leukemia cells to chemotherapy. As an important element of the tumor
microenvironment, the cancer-associated fibroblasts (CAFs) are considered to be activated modulators in the
chemo-resistance of many solid tumors. But their contribution to AML has yet to be fully understood. Here we
report a critical role for CAFs which were thought to be a survival and chemo-protective factor for leukemia cells.
Methods: A retrospective study on the BM biopsies from 63 primary AML patients and 59 normal controls was
applied to quantitative analysis the fiber stroma in the BM sections. Then immunohistochemistry on the BM
biopsies were used to detect the makers of the CAFs. Their effects on drug resistance of leukemia cells were further
to be assessed by co-cultured experiments in vitro. Moreover, the possible mechanisms involved in CAF-mediated
chemo-protection of AML cells was investigated by antibody neutralization and siRNA knockdown experiments,
with particular emphasis on the role of GDF15.
Results: In our study, excessive reticular fibers in the BM led to higher frequency of relapse and mortality in primary
AML patients, bringing the inspiration for us to investigate the functional roles of the fiber-devied cells. We declared
that the CAF cells which expressed higher levels of FSP1, α-SMA or FAP protein were widely distributed in the marrow
of AML. Then in vitro co-cultured tests showed that these CAFs could protect leukemia cell lines (THP-1/K562) from
chemotherapy. Interestingly, this effect could be decreased by either treatment with a neutralizing anti-GDF15
antibody or knockdown GDF15 (with siGDF15) in CAFs. Furthermore, we also confirmed that the GDF15+ cells mainly
co-localized with FAP, which was identified as the typical phenotype of CAFs in the BM stroma.
Conclusions: We firstly demonstrate that the functional CAFs are widespread within the BM of AML patients and
should be a critical chemo-protective element for AML cells by producing amount of GDF15.
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Background
Chemo-resistance remains a significant challenge in acute
myeloid leukemia (AML) and is one of the critical prognos-
tic elements. Evidence has suggested that the interaction
between leukemia cells and the BM stroma could affect the
chemo-sensitivity of the tumor cells [1]. As an important
element of the tumor microenvironment, fibroblasts with
an activated phenotype, referred to as ‘activated myofibro-
blasts’ or ‘cancer-associated fibroblasts’ (CAFs), have been
reported to play a critical role in the chemo-resistance of
solid tumors [2]. However, CAFs still appear not to be a
concern in leukemia because BM biopsies are not routinely
performed in AML patients. Therefore, whether CAFs exist
in the BM microenvironment and whether they are in-
volved in resistance to chemotherapy still remain unclear.
CAFs display phenotypes that are similar to those of
myofibroblasts derived from quiescent fibroblasts, which
are activated when they interact with carcinoma cells dur-
ing tumorigenesis [3]. These powerful cells are immuno-
logically defined primarily by the expression of α-smooth-
muscle actin (α-SMA), fibroblast-activated protein (FAP),
and fibroblast-specific protein 1 (FSP1) [4–6]. Datas have
revealed that CAF cells are involved in the migration,
growth and chemo-resistance of tumor cells in several
solid tumors, including human prostate, pancreatic, colo-
rectal carcinoma, and in hematologic malignancies, such
as multiple myeloma, and the function mainly by secreting
a variety of cytokines [7–9]. In the BM from mouse
models of acute lymphoblastic leukemia (ALL), we have
previously determined a protective niche, which is dynam-
ically transient between Nestin+ and α-SMA+ cells,causing
the production of reticular fibers in response to chemo-
therapy. CAF-like cells and fibers may provide chemore-
sistance for leukemia cells in vivo. Meanwhile, leukemia
cells contribute to the protective niche formation by se-
creting chemotactic factors and growth factors, in particu-
lar, growth differentiation factor 15 (GDF15) [10]. GDF15,
a divergent member of the TGF-β superfamily, is highly
expressed only in the placenta and in macrophage cells
under physiological conditions [11]. However, it is clinic-
ally associated with disease progression in numerous tu-
mors [12–14]. Recently, it has been demonstrated that
CAFs could be a novel source of GDF15 in human pros-
tate cancer and multiple myeloma [7, 15]. We propose
that CAFs within the BM of AML could also counter the
chemo-sensitivity of leukemia cells by producing GDF15.
In the current study, excessive reticular fibers in the BM
led to a poor prognosis in primary AML patients, making
it important to investigate the functional roles of the fibro-
blast cells. After demonstrating the presence of CAFs in
the marrow microenvironment of primary AML and their
ability to protect leukemia cells from chemotherapy agents
in vitro, we assessed whether GDF15 contributed to the
CAF-mediated chemo-protection of AML cells either by
using a neutralizing anti-GDF15 antibody or by knocking
down GDF15 (siGDF15) in the CAFs as well as by investi-
gating the distribution of GDF15 in the cytoplasm of
CAFs within BM sections from AML patients. These find-
ings were used to investigate the functional roles of CAF-
derived GDF15 in chemo-resistance of leukemia and
whether CAF cells, by producing GDF15, could be a sur-
vival and chemo-protective element for leukemia cells.
Methods
Primary AML samples and normal controls
Primary AML patients except acute promyelocytic
leukemia (n = 63) were prospectively enrolled in our
study after providing written informed consent. Cases of
newly diagnosed lymphoma patients without bone mar-
row involvement were selected as the normal control
group (n = 59). There were no statistical differences in
age and sex between these two groups (data were not
shown). The studied patients with AML received the in-
duction/reinduction chemotherapy protocols and all the
BM trephine biopsy specimens and BM aspirates were
obtained from Shanghai Jiaotong University-affiliated
hospitals (Shanghai, China). The patients were diagnosed
according to the FAB classification. Complete remission
(CR) and relapse were diagnosed according to Cheson et
al [16]. And the refractory AML cases were defined in
accordance with Schmid et al [17]. The AML patient
characteristics are presented in Table 1. The pathologists
who examined the BM samples were not participant in
this study and were innocent about the group situation.
Cell culture and regents
Mesenchymal stem cells (MSCs) were obtained from the
BM of primary AML patients after informed consent. The
marrow was diluted twice with phosphate buffered saline
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(PBS), and then isolated by Ficoll-Hypaque (Axis-Shield
Diagnostics, Dundee, Scotland, UK) density-gradient centri-
fugation. Monocytes were collected by adherence to a plas-
tic flask and incubated for 48h in MesenCult® medium
(STEMCELL Technologies, Vancouver, BC, Canada). The
phenotype and multipotential differentiation of MSC cells
used in the study has been verified (Additional file 1: Figure
S1–2). Then BM-MSCs were treated with recombinant hu-
man TGF-β1 (10ng/ml, R&D Systems, Minneapolis, MN,
USA) to trigger CAF differentiation. Conditioned medium
from the CAFs or MSCs was obtained from cells cultured
in regular medium with 1 % FBS. The leukemia cell lines
THP-1 and K562 (American Type Culture Collection,
Manassas, VA, USA) were cultured in 1640 or low-glucose
DMEM supplemented with 10 % fetal bovine serum (FBS)
and penicillin-streptomycin (Gibco, Grand Island, NY,
USA) at 37 °C in 5 % CO2. Additionally, where appropriate,
the leukemia cells were pre-incubated with the TGF-β1 in-
hibitor SB431542 (Sigma, St Louis, MO, USA) for 2 h at 37
°C in 5 % CO2.
Transwell co-culture of CAFs with leukemia cells
CAF cells (2 × 104 initial cell count) were cultured for 24
h in the upper side of a transwell chamber partitioned
by a polycarbonate membrane (8.0um pore size, Corning
Incorporated, Costar). And 2 × 105 THP-1and K562 cells
were co-cultured in the lower part in 1640 or DMEM
medium with 10 % FBS at 37 °C, 5 % CO2 for 48 h.
Evaluation of leukemic cell viability
THP-1 and K562 cells from suspension cultured, direct co-
cultured or transwell co-cultured groups were treated with
Ara-C (10uM, TCI Company, Tokyo chemical industry,
Tokyo, Japan) for 48 h. Directly co-cultured THP-1/K562
cells were separated from the MSCs or CAFs monolayer by
careful pipetting. After the leukaemic cells were collected,
the monolayer was observed under the microscope (100×)
to confirm that the monolayer was not damaged and that
fewer than 10 leukaemic cells/vision field remained at-
tached. Cell viability was evaluated by trypan blue exclusion
in triplicate samples and quantified by a Cellometer Mini
(Nexcelom, Lawrence, MA, USA).
Immunohistochemistry and the reticulin fiber density
(RFD) assay
The BM tissue samples were used for immunohistochem-
istry and Gomori’s stain. The rabbit anti-FSP1/S100A4
monoclonal antibody (Millipore, Billerica, MA, USA),
rabbit anti-FAP polyclonal antibody (Abnova, Taipei,
Taiwan), goat anti-α-SMA polyclonal antibody (Abcam,
Cambridge, MA, USA), rabbit anti-GDF15 monoclonal
antibody (Cell Signaling, Danvers, MA, USA), mouse anti-
Vimentin monoclonal antibody (Santa Cruz, Dallas, CA,
USA), and mouse anti-CD68 monoclonal antibody
(Abcam) incubations were performed according to the
manufacturer’s instructions. Images of the slides stained
for these markers were scanned at 40× magnification
using the optical microscope (Olympus Co., Tokyo,
Japan). The positive rate of each marker was quantified by
counting the ratio of the positive cells in all nuclear cells.
The reticulin fiber density (RFD) of the samples was
assessed according to Norén-Nyström et al [18]. All read-
ings and estimations were performed in a blinded manner.
Flow cytometry
The Alexa Fluorescence488 (AF488)-conjugated monoclo-
nal antibodies specific for α-SMA (R&D Systems, Minne-
apolis, MN, USA), a rabbit anti-FAP polyclonal antibody
(Abcam, Cambridge, MA, USA) and a FITC-conjugated
anti-rabbit polyclonal antibody were used (eBioscience, San
Diego, CA, USA). The appropriate isotype-matched anti-
bodies were used as controls (R&D Systems). For the apop-
tosis assay, THP-1 and K562 cells (5 × 105) were stained
with Annexin-V and propidium iodide (PI) for apoptosis
detection (BD, Franklin Lakes, New Jersey, USA) according
to the recommended protocol on a Becton Dickinson Flow
Cytometer. For cell cycle analyses, THP-1 cells were
treated with RNase A and PI (Sigma, St Louis, MO, USA).
The measurements were made using a flow cytometer
(Beckman, Urbana, IL, USA).
Quantitative reverse transcription PCR (qRT-PCR)
Total RNA was extracted using Trizol (Invitrogen, Paisley,
UK), and the RNA was converted into cDNA using the
Primer Script TM RT reagent Kit (Takara Bio Inc, Otsu,
Shiga, Japan). All real-time PCR reactions were performed
using an ABI 7500 real-time PCR system (Biosystems,
Foster City, CA, USA) and the SYBR Premix Ex Taq re-
agent kit (Takara Bio Inc).
Western blotting and ELISA
MSC or CAF cells were harvested in a radioimmuno-
precipitation assay buffer for western blotting analysis
(Beyotime, Haimen, Jiangsu, China). Mouse anti-
collagen I monoclonal antibody (Abcam, Cambridge,
MA, USA), rabbit anti-collagen III polyclonal antibody
(Abcam), rabbit anti-FAP polyclonal antibody (Abnova,
Taipei, Taiwan), rabbit anti-α-SMA monoclonal anti-
body (Epitomics, Burlingame, CA,USA), rabbit anti-
GDF15 polyclonal antibody (Bioworld, Louis Park,
MN,USA) and mouse anti-β-actin monoclonal mono-
clonal antibody (Cell Signaling, Danvers, MA, USA)
were used. Antigen detection was performed using a
goat anti-rabbit or an anti-mouse IgG secondary anti-
body (Cell Signaling) conjugated to HRP and an ECL
western blotting substrate (Pierce, Waltham, MA,
USA). The BM aspirates were collected from newly di-
agnosed AML patients which were divided into CR
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group (n = 9) and refractory group (n = 8) and normal
controls (n = 11). The ELISA analysis for GDF15 was
performed according to the manufacturer’s instructions
(R&D systems).
RNA interference
GDF15 siRNA and the control siRNA products were pur-
chased from Gene Pharma Company (Suzhou, Jiangsu,
China). Transfection of siRNA was performed using
Lipofectamine2000 (Panc05.04) or Lipofectamine RNAi-
Max (Invitrogen, Paisley, UK) following the manufacturer’s
protocol. The validation of target gene knockdown was per-
formed using qRT-PCR using the delta-delta CT method.
Statistical analyses
A Mann-Whitney U test was applied to compare the
RFD of the AML patients and the normal controls. The
statistical analyses were performed using the two-sample
two-tailed Student’s t-test. The survival curves were con-
structed using the Kaplan–Meier method, and the log-
rank test was used to test the difference in RFS and OS
between cases with different RFD values. RFS was de-
fined as the time between diagnosis and the onset of the
first relapse, and OS was defined as the time between
diagnosis and the occurrence of death or when lost to
follow-up. Independent prognostic parameters for OS
and RFS were identified by univariable Cox regression
analyses and a multivariable Cox regression model using
backward elimination with an exclusion significance
level of 5 %. The data are described as the mean ± stand-
ard deviation (SD), and p values ≤0.05 were considered
significant. All statistical analyses were conducted by
using the SPSS 18.0 software program (SPSS, Chicago,
IL, USA).
Results
Characteristics of the patients
The median ages of patients in the refractory group (n =
25) and CR group (n = 38) were 53 years (range: 23-
82years) and 60 years (range: 18–80years) respectively. The
ratios of male/female in these two groups were 18/7 and
27/11 respectively (Table 1). There were no statistical differ-
ences in age, sex and FAB subtypes between the two
groups.
RFD is higher in AML and correlates with the
chemotherapy outcome
Some data have indicated that increased fibrosis in the
BM is a physical barrier against the effective delivery of
therapeutic agents in childhood acute lymphoblastic
leukemia (ALL) [19]. In our study, Gomori staining
showed that abnormally proliferated reticular fiber,
shown as black silk filaments, was distributed more
densely in refractory AML patients (Fig. 1a). The RFD
score in the refractory patients was higher when com-
pared to the CR group, and both of them were signifi-
cantly higher than the control (Fig. 1b). Furthermore,
the Cox’s regression model showed that only the factor
of RFD was associated with higher risk of relapse and
death (P = 0.029 and 0.000, respectively) (Table 2). This
was further illustrated in a Kaplan-Meier survival ana-
lysis. The cutoff used for low and high RFD was decided
by exploring RFD data in Cox’s analyses dividing the ma-
terial by the median and quartiles. In the AML-CR
group, there was a poorer prognosis in RFS for cases
with RFD > 1.13 % (Fig. 1c). And in all the AML pa-
tients, we also concluded that patients with RFD score
of more than 3.68 % revealed a shortened overall sur-
vival (Fig. 1d). However, there was no correlation be-
tween the RFD score and blasts either in the peripheral
blood or in the BM (Figs. 1e-f ), suggesting that the fibers
neither anchor the leukemia cells in the BM nor pro-
mote blast proliferation. Therefore, we hypothesized that
the fibers may not directly affect AML patient prognosis,
although the RFD score indicated a poor outcome in
AML patients. Based on this information, we focused on
the reticulin fiber-derived cells.
The reticulin fibers were mainly derived from the CAFs in
AML
The fibers in the BM were derived mainly from mesen-
chymal cells which were a heterogeneous population
mainly comprised of adipocytes, macrophages and fibro-
blasts [20–22]. As we all know that adipocytes are sel-
dom found in the BM of primary AML, therefore,
adipocytes were not assessed in the survey. The mesen-
chymal markers Vimentin, FSP1, α-SMA and FAP were
immunoassayed to identify fibroblasts, and macrophage
cells were identified by CD68. As illustrated in Fig. 2,
Vimentin, as a common marker of mesenchymal cells,
showed no difference in the BM from AML patients and
controls, indicating that the increased fibers in AML
may originate from some special subpopulations of mes-
enchymal cells. However, there represented no difference
in the positive rate of CD68 in the BM between these
two subgroups, indicating that macrophages did not
contribute to fibrosis in AML. Among the other mesen-
chymal markers, there was a significant increase in the
cells positive for FSP1, α-SMA or FAP in the AML sam-
ples compared to the controls, and these are common
markers of CAFs [23]. We thus hypothesis that the
amount of CAFs strongly contributed to the increased fi-
bers in AML, and we further to explore whether CAFs
could play particular functions in AML progression.
CAFs protect leukemia cells from chemotherapy
We focused on the protective effects of the CAFs in the
leukemia cells from chemotherapy. As illustrated in
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Fig. 3a-c, under TGF-β1 treatment, the stroma cells ex-
hibited a larger volume and an increase in cytoplasmic
content and uniformly expressed α-SMA and FAP on
the cell membrane as assessed by flow cytometry. These
cells also had the capacity to synthesize higher levels of
collagen I, collagen III, α-SMA and FAP protein as mea-
sured by western blotting, which further confirmed that
MSCs could be transformed into CAF cells by TGF-β1.
Co-cultured experiments showed that the mean survival
of the CAF co-cultured leukemia cells was significantly
Fig. 1 The RFD score is higher in AML and is related to outcome. a Examples of the Gomori staining of reticulin fibers in the BM sections from normal
controls and AML patients, which were further divided into CR and refractory groups. Both images are at a magnification of 1000×. b The RFD for the
AML-CR (n= 38) and AML-refractory (n= 25) patients compared to the normal controls (n= 59), ***p < 0.001 (c) RFS of AML-CR patients subdivided into
high (>1.13 %) and low (≤1.13 %) RFD groups, P= 0.003. d OS of all the AML patients subdivided into high (>3.68 %) and low (≤3.68%) RFD groups,
P< 0.001. e-f Scatter plot: RFD vs. blasts in the peripheral blood and the blasts in the BM of primary AML patients using linear regression analysis (P= 0.47
and 0.70 respectively)
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increased compared with the cells co-cultured with the
MSC or cultured alone (Fig. 3d). Leukemia cells co-
cultured with the CAFs exhibited less apoptosis as deter-
mined by AnnexinV/PI staining analysis (Fig. 3f ), sug-
gesting that CAF reduce the sensitivity of the leukemia
cells to chemotherapeutic agents. Moreover, the cell
cycle status of the residual leukemia cells revealed an in-
creased number of cells which arrested in the G0/G1
phase, indicating that the CAFs protected the leukemic
cells by maintaining them in a quiescent phase thus
decreasing their chemotherapy sensitivity (Fig. 3e). To
verify the effect of soluble factors secreted by CAFs on
the chemotherapy sensitivity of the leukemia cells, trans-
well experiment was carried out to prevent direct con-
tact but permit exchange of soluble diffusible factors. As
shown in Fig. 3g, the viable cell numbers in the transwell
system were significantly increased when compared to
the suspension cultured subgroup (p < 0.001). Further-
more, when the leukemia cells cultured in the CAF-CM
as described in the methods above, the viability of the
Table 2 Cox regression for overall survival (OS) and relapse-free survival (RFS)
RFS OS
Variable n HR 95% CI P n HR 95% CI P
PWBC (109/L) 38 1.009 0.988-1.030 0.420 63 1.003 0.988-1.019 0.674
Age (years) 38 0.950 0.974-1.025 0.950 63 1.002 0.976-1.030 0.862
BMP (%) 38 0.987 0.965-1.010 0.275 63 0.990 0.971-1.010 0.330
RFD (%) 38 1.400 1.035-1.892 0.029 63 1.755 1.331-2.312 0.000
Abbreviations: PWBC peripheral white blood cell, BMP Bone marrow precursors, RFD reticulin fiber density, HR hazard ratio, CI confidence interval
Fig. 2 The reticulin fibers were mainly derived from CAFs in AML. Microphotographs displaying IHC staining for Vimentin, FSP1, α-SMA, FAP and
CD68 in the BM sections of the normal controls and primary AML patients. Both images are at a magnification of 400×. The horizontal bar below
the images indicates the percentage of positive cells that expressed Vimentin, FSP1, α-SMA, FAP and CD68 in the BM sections between these two
groups (n = 3),**p < 0.01
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leukemia cells was decreased when the ratio of the CAF-
CM was reduced (Fig. 3h). SB431542, which is consid-
ered to be a TGF-β receptor (ALK4/5/7) inhibitor, could
partly abolished the protective effects of the CAFs for
the tumor cells from chemotherapy (Fig. 3i), indicating
that the chemo-protection for AML cells from CAF was
mediated by some soluble substances, most likely TGF-β
superfamily.
GDF15 contributes to the CAF-mediated chemo-
protection of AML cells
Based on our previous results showing that GDF15 was
markedly up regulated in the residual leukemic cells after
chemotherapy [10] and reports that GDF15 confers drug
resistance to other cancer cells [24–27], we questioned
whether CAFs in the BM could also play an important role
by secreting GDF15. As shown in Fig. 4a-c, the GDF15 in
Fig. 3 CAFs protect leukemia cells from chemotherapy a Morphological observations of the MSCs and the CAFs. Both images are at a
magnification of 100×. b Flow cytometry analysis showed expression levels of a-SMA and FAP in the MSCs and the CAFs. c Western blotting for
collagen I, collagen III, FSP1, α-SMA and FAP in the MSC and the CAF cells. d Bar plots illustrating the viability of THP-1 and K562 cells which were
cultured in medium alone or direct co-cultured with MSCs or CAFs under treatment of Ara-C (10uM) for 48 h. e Cell cycle of the residual THP-1
cells which were treated with Ara-C (10uM) for 48 h when co-cultured with CAFs or not were analysized by propidium iodide staining and flow
cytometry. f Apoptosis of THP-1 and K562 cells which were co-cultured with CAFs (right) or not (left) were evaluated by AnnexinV/PI staining and
flow-cytometry. Data were presented for one of the triplicate experiments. g Bar plots showed the viability of THP-1 and K562 which were cultured in
medium alone or co-cultured with CAFs in a transwell system under treatment of Ara-C (10uM) for 48 h. h The THP-1 and K562 cells were cultured in
medium with different ratios of CAF conditioned medium (CAF-CM) under treatment with Ara-C (10uM) for 48h. i: The viable cells of THP-1 (white bar)
and K562 (gray bar) which were co-cultured with a CAF layer under Ara-C treatment for 48h after pretreated with SB431542 or not were evaluated
by trypan blue exclusion assay Data were presented as mean ± SD of triplicate experiments.* p < 0.05,** p < 0.01, ***p < 0.001
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the cell lysates of the CAFs was significantly increased
when compared to MSCs and was further abundantly re-
leased into the culture supernatant, confirming that the
CAFs secreted enough GDF15. To further investigate the
functional roles of GDF15, the neutralizing anti-GDF15
antibody was added to the co-cultured system. As shown
in Fig. 4c, under the treatment of Ara-c and the neutraliz-
ing anti-GDF15 antibody, the survival of THP-1 was de-
creased. In addition, we knocked down GDF15 in the
CAFs with a small interfering RNA targeting GDF15
(siGDF15) and then validated by RT-PCR analysis (Fig. 4d).
As shown in Fig. 4e, these CAF cells nearly lost their po-
tential to protect THP-1 cells from chemotherapy. Our re-
sults demonstrating that GDF15 substantially contributes
to the CAF-mediated chemo-protection of AML cells.
GDF15 in the BM of AML patients
To further confirm the pathophysiological contribution
of GDF15 in CAFs, the amount of GDF15 in the BM as-
pirates was compared between the normal controls and
Fig. 4 GDF15 contributed to the CAF-mediated chemo-protection of the AML cells. (a-c) Western blot, ELISA and Quantitative RT-PCR analyses
represented GDF15 expression in the MSC and the CAF cells. d The bar plots showed the relative viability of the THP-1 cells cultured in medium
alone or co-cultured with CAFs added with or without an anti-GDF15 antibody under the treatment of Ara-c (10uM) for 48 h. e Quantitative RT-
PCR showing GDF15 expression in the CAFs after nucleofection of a GDF15-specific siRNA or a non-targeting control siRNA for 48 h. f The number
of viable THP-1 cells cultured in medium alone or direct co-cultured with the layer of CAFs after nucleofection of GDF15-siRNA or not under the
treatment of Ara-C (10uM) for 48 h. The data are the result of three independent experiments and are presented as means ± SD,*p < 0.05,
**p < 0.01, ***p < 0.001
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the primary AML patients. To avoid the confounding ef-
fects of therapy-induced elevations of GDF15, the BM
aspirates were derived from treatment-naïve patients. As
shown in Fig. 5a, GDF15 in the BM aspirates from
AML-refractory group was higher than the AML-CR
group and both of them were significantly higher than
the control group. To further investigate the distribution
of GDF15 in the BM, immunohistochemistry analyses
were performed in the BM biopsies. As illustrated in
Fig. 5b, GDF15 was constitutively expressed in the cyto-
plasm of spindle cells, which were clearly observed in
the BM biopsies from the AML patients, whereas these
cells were scarcely in the controls. In addition, immuno-
assays on the serial sections showed that these GDF15+
cells were mainly co-localized with FAP, which was iden-
tified as the typical immunophenotype of the CAFs
(Figs. 5c). These results confirmed the possibility that
GDF15 contributes to the CAF-mediated chemotherapy
protection for leukemia cells.
Discussion
As it is known that the normal tumor microenvironment
becomes ‘corrupted’ during tumor development, which
is reflected by appearance of a large and heterogeneous
category of cancer-associated fibroblasts (CAFs) [28].
CAF cells are considered active modulators of the tumor
microenvironment among many solid tumors [29–31].
However, few studies have directly addressed the role of
the CAFs in the BM of leukemia. In the present study,
we demonstrate that functional CAFs are widespread in
the BM of AML patients and could serve as a critical
chemo-protective element for AML cells by producing
an abundance of GDF15.
As we all know, AML cells interact both anatomically
and functionally with the stroma within the BM micro-
environment. These interactions have a critical role in
the development, progression and relapse of AML. A re-
cent study has suggested discoidin domain receptor 1
(DDR1), a class of collagen-activated receptor tyrosine
kinase (RTK) was highly upregulated on bone marrow
(BM)-derived CD33+ leukemic blasts of acute myeloid
leukemia (AML) patients, suggesting that the remodeled
collagen IV in BM microenvironment could modulate
the migration and adhesion of myeloid leukemia cells
during leukemogenesis [32]. In this study, the RFD and
the immunohistochemistry assay were used to detect the
Fig. 5 GDF15 expressed in the BM of AML in vivo. a ELISA analysis of GDF15 levels in the BM aspirates of the controls (n = 11) and treatment-
naïve AML-CR (n = 9) and AML-refractory patients (n = 8) *** p < 0.001vs the control group. b Examples of immunohistochemistry for GDF15 in
the BM sections of the normal control and the primary AML patient. Both images are at a magnification of 400×. c Immunohistochemistry
identifies cells that express FAP (arrows) and GDF15 (arrowheads) in the AML patients. GDF15 could also be detected in the leukemia cells
(triangle). The images on the left are at a magnification of 400× and on the right are at a magnification of 1000×
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transformation of the stroma niche in BM during acute
leukemogenesis. It has been reported that reticulin in
BM is mainly composed of individual fibrils or small
bunches of fibrils of type III collagen surrounding a core
of type I collagen fibrils [20]. Our experiments also con-
firmed the presence of the amounts of collagen I and
collagen III in the marrow of AML (Additional file 1:
Figures S3). This result is in agreement with those from
previous studies, which have revealed that CAFs might
produce and secrete various extracellular matrix proteins
(i.e., collagen I, III, IV) in solid tumors [33]. Data has
been proposed that CAFs are responsible for collagen
synthesis in the stroma of human hepatocellular carcin-
oma [34]. But reports about the origin of the fiber is still
rare, to our knowledge, Jean Y P et al. firstly developed
the quantitative dissection of stromal cell-extracellular
matrix interactions in living tissue by using multiphoton
laser scanning microscopy and second harmonic gener-
ation (SHG) of fibrillar collagen. They showed that the
CAF is necessary for fiber remodeling [35]. Based on the
support from the literatures, we considered that the in-
creased fiber stroma in BM might imply the increased of
CAFs during leukemogenesis. Positive staining for the
CAF-specific markers α-SMA, FAP and FSP1 could also
displayed that amount of the CAFs contributed to the
abundant fibers in the BM. In addition, there existed
sufficient TGF-β1 in BM microenvironment of leukemia
to stimulate the formation of CAF niche (Additional file
1: Figure S4).
Resistance to anti-cancer therapies which is the major
obstacle to a better prognosis of patients obtained in-
creasingly attention in the modern biomedical research
[36]. Acting on cancer cells, CAFs have previously been
reported to be involved in resistance to chemotherapy in
many solid tumors. Our co-cultured experiments
showed that these functional fibroblasts could also ex-
hibit a chemo-protective effect on the leukemia cells. It
is worth noting that our results did no find the similar
protective effects of the stroma cells which were derived
from the healthy donors and pretreated with TGF-
β1(10ng/ml) for 14 d (Additional file 1: Figure S5). We
suspected this may be due to the differences in BM-
MSC themselves between the AML patients and the
healthy ones. The mechanisms involved in the anti-
chemotherapy effects of CAFs on AML cells are not
clear. In this report, we detected that either knockdown
of GDF15 in the CAFs or interference by neutralizing
anti-GDF15 in the co-culture system decreased the mor-
tality of the THP-1 cells, confirming that GDF15 has an
essential function in the CAF-mediated chemotherapeu-
tic resistance of the leukemic cells. When compared with
MSC and the THP-1 cells, we detected an increased
GDF15 concentration in the conditioned medium of the
CAFs (Additional file 1: Figure S6). Therefore, we
assumed that CAFs were likely to be the main contribu-
tor to the high concentrations of soluble GDF15, which
was different form our previous publication that GDF15
derived from leukemia cells conferred chemoresistance
in acute lymphoblastic leukemia, we suspect there
existed originally differences in the lymphoid and mye-
loid leukemia cells. As we all know that GDF15, as an
important component of the TGF-β superfamily, is not-
ably increased in patients with prostate, colorectal, or
pancreatic cancers and has been described as an import-
ant biomarker of poor clinical outcome [37–39]. How-
ever, the GDF15 concentrations in the BM of AML
patients are not well defined. In our experiments, the
direct evidence for the CAFs contributing to high
GDF15 expression is supported by the BM biopsies,
which indicated that this factor was mainly expressed by
the CAFs and colocalized with FAP by immunohisto-
chemistry. GDF15 is present both on the membrane and
in the cytoplasm of leukemic cells (Fig. 5c), suggesting
that leukemia cells have an autocrine function, which is
consistent with the results of ELISA analysis of the
leukemia cell lines in vitro. Both the CAFs and the
leukemia cells secreted GDF15, suggesting that GDF15
plays a critical role in the local cross-regulation between
the leukemia cells and the CAFs within the BM in pri-
mary AML patients. However, the detection of CAF cells
on BM biopsies were not routinely performed in AML
patients, so if there resist a correlation between CAF
density and AML survival still remains unclear. Based
on this, it is necessary for us to construct the mouse
transplantation models of AML to explore the correl-
ation between CAF density and further to explore the
potential mechanisms in vivo.
Conclusions
This study highlights the importance of the fiber
stroma in leukemogenesis. The abundant reticulin
fiber predicts a poor outcome of AML. Based on the
experiments, we suggest that a portion of the CAF
cells exist in the BM microenvironment of AML. And
these functional cells affected the chemosensitivity of
the leukemia cells by producing GDF15. Disrupting
GDF15 via treatment with an anti-GDF15 antibody or
si-GDF15 in the CAFs abrogated the protection of
the leukemic cells by CAFs. To our knowledge, this is
the first report of the molecular mechanisms of CAFs
in AML. We suspect that there might maintain a
chemo-protective niche in a pool of AML cells causes
the relapse, which may need for further animal exper-
iments to verification. In this regard, future studies
from our laboratory will assess GDF15 as a novel tar-
get for therapeutic strategies in AML in vivo by using
a mouse transplantation model of AML.
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Additional file
Additional file 1: Figure S1. Phenotype characterization of BM-
MSCs. Flow Cytometry analysis showed that almost all the cultured
MSC expressed CD90, CD105 and CD73, while a small portion of MSC
expressed CD14, CD34 and CD45. Figure S2. Differentiation potential of BM-
MSCs. (a) MSC differentiation to adipocytes was shown by Oil-O-Red staining.
(B) And osteoblast differentiation was detected by Alizarin Red staining. The
images are at a magnification of 200×. Figure S3. Immunohistochemistry to
detect the expression of collagen I and collagen III in the BM of the normal
control and the AML patient. Both images are at a magnification of 400×.
Figure S4. The levels of TGF-β1 in BM plasma between AML patients and the
normal controls were analyzed by the Quantikine ELISA kit ((R&D Systems,
USA), according to the manufacturers instruction. The absorbance at 450 nm
was detected by the microplate reader. Concentrations were calculated from
the constructed linear curve. Data are presented as the mean ± standard
deviation; n= 5 per group. *** p< 0.01. Figure S5. Bar plots illustrating the
viability of leukemia cells (THP-1 and K562) under treatment of Ara-C (10uM)
for 48 h. THP-1/K562 cells were cultured in medium alone or co-cultured with
the stroma cells derived from BM-MSC of healthy donors and pretreated with
TGF-β1(10ng/ml) or not. The error bars represent the standard error of the
mean of three replicates, ns, p> 0.05. Figure S6. The horizontal bar showed
Elisa analysis of GDF15 in the supernatants of the MSC, THP and CAF cells.
The data represent the mean ± SD of triplicate experiments, ** p < 0.01.
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